Literature DB >> 22964534

Rheumatoid arthritis: Threshold for success in RA drug development.

Stanley B Cohen1.   

Abstract

Determining the potential success of investigational therapies for rheumatoid arthritis early in the development process would enable better allocation of increasingly limited resources. Such ‘go or no-go’ decision-making could be improved by a method of analysing longitudinal clinical trial data to establish a threshold for success of a new drug.

Entities:  

Mesh：

Year:  2012        PMID： 22964534     DOI： 10.1038/nrrheum.2012.150

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


  7 in total

1.  Model-based meta-analysis for comparative efficacy and safety: application in drug development and beyond.

Authors:  J W Mandema; M Gibbs; R A Boyd; D R Wada; M Pfister
Journal:  Clin Pharmacol Ther       Date:  2011-12       Impact factor: 6.875

2.  Remission of rheumatoid arthritis in clinical practice: application of the American College of Rheumatology/European League Against Rheumatism 2011 remission criteria.

Authors:  Shadi H Shahouri; Kaleb Michaud; Ted R Mikuls; Liron Caplan; Timothy S Shaver; James D Anderson; David N Weidensaul; Ruth E Busch; Shirley Wang; Frederick Wolfe
Journal:  Arthritis Rheum       Date:  2011-11

3.  A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry.

Authors:  Jeffrey D Greenberg; George Reed; Dennis Decktor; Leslie Harrold; Daniel Furst; Allan Gibofsky; Ralph Dehoratius; Mitsumasa Kishimoto; Joel M Kremer
Journal:  Ann Rheum Dis       Date:  2012-01-30       Impact factor: 19.103

4.  Longitudinal model-based meta-analysis in rheumatoid arthritis: an application toward model-based drug development.

Authors:  I Demin; B Hamrén; O Luttringer; G Pillai; T Jung
Journal:  Clin Pharmacol Ther       Date:  2012-07-04       Impact factor: 6.875

5.  The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.

Authors:  Ferdinand C Breedveld; Michael H Weisman; Arthur F Kavanaugh; Stanley B Cohen; Karel Pavelka; Ronald van Vollenhoven; John Sharp; John L Perez; George T Spencer-Green
Journal:  Arthritis Rheum       Date:  2006-01

6.  Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial.

Authors:  Paul Emery; Ferdinand C Breedveld; Stephen Hall; Patrick Durez; David J Chang; Deborah Robertson; Amitabh Singh; Ronald D Pedersen; Andrew S Koenig; Bruce Freundlich
Journal:  Lancet       Date:  2008-07-16       Impact factor: 79.321

7.  Efficacy and safety of the human anti-IL-1β monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, Phase II, dose-finding study.

Authors:  Rieke Alten; Juan Gomez-Reino; Patrick Durez; Andre Beaulieu; Anthony Sebba; Gerhard Krammer; Ralph Preiss; Udayasankar Arulmani; Albert Widmer; Xavier Gitton; Herbert Kellner
Journal:  BMC Musculoskelet Disord       Date:  2011-07-07       Impact factor: 2.362
  7 in total
  1 in total

1.  Translational Biomarkers and Ex Vivo Models of Joint Tissues as a Tool for Drug Development in Rheumatoid Arthritis.

Authors:  Cecilie F Kjelgaard-Petersen; Adam Platt; Martin Braddock; Martin A Jenkins; Kishwar Musa; Emma Graham; Thorbjørn Gantzel; Gillian Slynn; Michael E Weinblatt; Morten A Karsdal; Christian S Thudium; Anne-C Bay-Jensen
Journal:  Arthritis Rheumatol       Date:  2018-07-24       Impact factor: 10.995
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.